MEDP

The company is trading at 26x expected earnings despite earnings only expected to grow in the high single digit range. I'd say the company is "fairly" valued at this point in time relative to its trajectory.

In addition to this, the company did report a relatively soft third quarter in which bookings fell quite a bit due to what the company calls

"higher-than-normal cancellation levels during the quarter, primarily attributed to biotech firms facing financial constraints."

This would worry me a bit, simply due to the current economic environment. I'd be waiting to see if the soft bookings continue before I'd pull the trigger. Would be firmly on my watch list at this point in time.